deltatrials
Completed PHASE2 INTERVENTIONAL NCT00498407

A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer

Sponsor: Clavis Pharma

Conditions Advanced Colorectal Cancer Colorectal Cancer
Interventions CP-4055
Updated 5 times since 2017 Last updated: Jun 3, 2009 Started: May 31, 2007 Primary completion: Dec 31, 2008 Completion: Dec 31, 2008
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00498407, this PHASE2 trial focuses on Advanced Colorectal Cancer and Colorectal Cancer and remains completed. Sponsored by Clavis Pharma, it has been updated 5 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Clavis Pharma
Data source: Clavis Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations